{"article":{"annotation":{"article_id":"opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026","available_at":"2026-10-28T11:04:16.870016Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"4712843b4047716840920b947fcd48ef2842de8836741dbcfb73c1ee6835c1b2","input_sha256":"464be4140ad69bf4d194007c3f9d880027bb55f08bb545b3414d370bed5725d7","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"US","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.hhs.gov/press-room/hhs-reports-opioid-deaths-lowest-nearly-decade.html","https://www.healthaffairs.org/content/forefront/two-opioid-policy-trends-moving-right-direction-sustaining-decade-progress"]}],"geometry":null,"id":"iso3166-1:US","kind":"country-or-area","labels":{"ar":"الولايات المتحدة الأمريكية","en":"United States of America","es":"Estados Unidos de América","fr":"États-Unis d’Amérique"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"category+topics","language":"en","note":"Preserved editorial category/topic; broad candidate only","source_urls":["https://www.hhs.gov/press-room/hhs-reports-opioid-deaths-lowest-nearly-decade.html","https://www.healthaffairs.org/content/forefront/two-opioid-policy-trends-moving-right-direction-sustaining-decade-progress"]}],"method":"controlled-rules-v1","rule_id":"health-broad","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026?lang=en","category":"health","content":{"key_points":[],"paragraphs":["The U.S. Department of Health and Human Services published new analyses on October 27 describing a decade of change in prescription opioid exposure and pharmacy fills for two medications used in substance-use-disorder treatment. The underlying series, prepared by the Office of the Assistant Secretary for Planning and Evaluation, compares population-adjusted dispensing measures with their March 2015 levels through March 2026. In the latest period, opioid prescription fills stood at 45.3 percent of that baseline, total opioid dosage at 35.2 percent, and retail-pharmacy patients receiving opioid prescriptions at 49.6 percent. The number of patients filling prescriptions for buprenorphine or naltrexone was 218 percent of its baseline.","The measures describe distinct parts of a changing treatment landscape. The analysis uses three-month moving averages per 100,000 population and indexes each series to March 2015 = 100. Prescription counts and dosage include retail and mail channels, while the patient count for opioid prescriptions is based on retail dispensing. For buprenorphine and naltrexone, prescription measures include retail and mail but patient counts identify people with retail fills; the study excludes two buprenorphine formulations commonly used for pain. Thus the 218 percent figure is not a count of all people receiving treatment for opioid use disorder, and the analysis does not include methadone dispensed through certified opioid treatment programs.","The authors report that total morphine milligram equivalents, a standardized dosage measure that adjusts for different opioid drugs and strengths, declined more than prescription counts. They say that pattern is consistent with lower average dosage exposure as well as fewer prescription transactions. The patient-count measure also fell, indicating fewer people received prescription opioids through the measured retail channel. On the treatment side, patient counts for buprenorphine or naltrexone rose more than prescription counts: by March 2026, patient fills were 218 percent of baseline and prescriptions were 148.1 percent. The analysis suggests longer days supplied per prescription may help explain the divergence. These measures show pharmacy dispensing, not whether each person began or remained in clinical treatment.","Mortality context does not establish what caused the changes. The linked Health Affairs analysis explains that overdose estimates are provisional and may involve multiple drugs. It also describes how the illicit market shifted toward fentanyl, which can be more potent and easier to obtain than prescription opioids. In that setting, reducing prescription exposure is a prevention measure, but it is not by itself a sufficient explanation for mortality trends; substitution toward illicit drugs can alter risk in complex ways.","HHS’s announcement attributes the progress to policies across administrations, including prescribing changes, fentanyl enforcement and treatment programs, and highlights the 2025 SUPPORT Act reauthorization and a 2026 federal recovery initiative. The analyses document trends but do not isolate the effect of any one law or administration. They rely on population-adjusted IQVIA pharmacy data and identify limitations in channel coverage and treatment definitions. The authors emphasize that prescription counts alone can miss dosage and patient changes, while legal authority for treatment does not guarantee practical access to diagnosis, medication, follow-up and support. The results support cautious monitoring across multiple measures; they do not show that all opioid-related deaths have reached a decade low or that the same trend holds for every community."],"sections":[]},"corrections":[],"country":"US","data":{"blocks":[{"description":{"en":"Prescription and treatment-medication dispensing measures indexed to March 2015.","tr":"Mart 2015 düzeyine göre endekslenen reçete ve tedavi ilacı dağıtım ölçüleri."},"id":"opioid-measures","items":[{"basis":"observed","label":{"en":"Opioid prescriptions relative to baseline","tr":"Opioid reçeteleri başlangıç düzeyine göre"},"measure":{"aggregation":"rate","frequency":"monthly","geography":"united-states","id":"opioid-prescriptions-index","periodRole":"reference-period","unitCode":"percent"},"period":"2026-03","unit":"percent","value":45.3},{"basis":"observed","label":{"en":"Total opioid dosage relative to baseline","tr":"Toplam opioid dozajı başlangıç düzeyine göre"},"measure":{"aggregation":"rate","frequency":"monthly","geography":"united-states","id":"opioid-dosage-index","periodRole":"reference-period","unitCode":"percent"},"period":"2026-03","unit":"percent","value":35.2},{"basis":"observed","label":{"en":"Retail patients receiving opioid prescriptions relative to baseline","tr":"Opioid reçetesi alan perakende eczane hastaları başlangıç düzeyine göre"},"measure":{"aggregation":"rate","frequency":"monthly","geography":"united-states","id":"opioid-patients-index","periodRole":"reference-period","unitCode":"percent"},"period":"2026-03","unit":"percent","value":49.6},{"basis":"observed","label":{"en":"Patients filling buprenorphine or naltrexone relative to baseline","tr":"Buprenorfin veya naltrekson reçetesi alan hastalar başlangıç düzeyine göre"},"measure":{"aggregation":"rate","frequency":"monthly","geography":"united-states","id":"oud-medication-patients-index","periodRole":"reference-period","unitCode":"percent"},"period":"2026-03","unit":"percent","value":218.0}],"methodology":{"en":"Pharmacy measures use population-adjusted three-month moving averages indexed to March 2015=100; values are the source-reported index levels.","tr":"Eczane ölçüleri nüfusa uyarlanmış üç aylık hareketli ortalamaları ve Mart 2015=100 bazını kullanır; değerler kaynakta yayımlanan indeks düzeyleridir."},"sourceUrls":["https://www.hhs.gov/press-room/hhs-reports-opioid-deaths-lowest-nearly-decade.html","https://www.healthaffairs.org/content/forefront/two-opioid-policy-trends-moving-right-direction-sustaining-decade-progress"],"title":{"en":"Opioid dispensing and treatment indicators","tr":"Opioid dağıtımı ve tedavi göstergeleri"},"type":"metrics","updatedAt":"2026-10-28T10:41:54Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026/data/opioid-measures?lang=en&format=csv","json":"https://newsverum.com/api/v1/articles/opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026/data/opioid-measures?lang=en&format=json"},"id":"opioid-measures"}],"data_types":["metrics"],"editorial_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-bb0644d7-5bd8-5f48-8f1b-277b4e3ecc40","event_period":"2026-03","event_period_basis":"event-or-reference-period","id":"opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026","image":null,"importance":0.6,"language":"en","modified_at":"2026-10-28T11:03:55+00:00","publication_basis":"publication-record","published_at":"2026-10-28T11:03:55+00:00","reading_minutes":3,"region":"world","relations":[],"section_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026","sources":[{"checkedAt":"2026-10-28","name":"U.S. Department of Health and Human Services","publishedAt":"2026-10-27","url":"https://www.hhs.gov/press-room/hhs-reports-opioid-deaths-lowest-nearly-decade.html"},{"checkedAt":"2026-10-28","name":"Health Affairs Forefront, ASPE analysis","publishedAt":"2026-10-27","url":"https://www.healthaffairs.org/content/forefront/two-opioid-policy-trends-moving-right-direction-sustaining-decade-progress"}],"summary":"HHS and ASPE analyses show lower prescription opioid dispensing and more patients filling two treatment medications, while leaving mortality causes unresolved.","text":"HHS and ASPE analyses show lower prescription opioid dispensing and more patients filling two treatment medications, while leaving mortality causes unresolved.\n\nThe U.S. Department of Health and Human Services published new analyses on October 27 describing a decade of change in prescription opioid exposure and pharmacy fills for two medications used in substance-use-disorder treatment. The underlying series, prepared by the Office of the Assistant Secretary for Planning and Evaluation, compares population-adjusted dispensing measures with their March 2015 levels through March 2026. In the latest period, opioid prescription fills stood at 45.3 percent of that baseline, total opioid dosage at 35.2 percent, and retail-pharmacy patients receiving opioid prescriptions at 49.6 percent. The number of patients filling prescriptions for buprenorphine or naltrexone was 218 percent of its baseline.\n\nThe measures describe distinct parts of a changing treatment landscape. The analysis uses three-month moving averages per 100,000 population and indexes each series to March 2015 = 100. Prescription counts and dosage include retail and mail channels, while the patient count for opioid prescriptions is based on retail dispensing. For buprenorphine and naltrexone, prescription measures include retail and mail but patient counts identify people with retail fills; the study excludes two buprenorphine formulations commonly used for pain. Thus the 218 percent figure is not a count of all people receiving treatment for opioid use disorder, and the analysis does not include methadone dispensed through certified opioid treatment programs.\n\nThe authors report that total morphine milligram equivalents, a standardized dosage measure that adjusts for different opioid drugs and strengths, declined more than prescription counts. They say that pattern is consistent with lower average dosage exposure as well as fewer prescription transactions. The patient-count measure also fell, indicating fewer people received prescription opioids through the measured retail channel. On the treatment side, patient counts for buprenorphine or naltrexone rose more than prescription counts: by March 2026, patient fills were 218 percent of baseline and prescriptions were 148.1 percent. The analysis suggests longer days supplied per prescription may help explain the divergence. These measures show pharmacy dispensing, not whether each person began or remained in clinical treatment.\n\nMortality context does not establish what caused the changes. The linked Health Affairs analysis explains that overdose estimates are provisional and may involve multiple drugs. It also describes how the illicit market shifted toward fentanyl, which can be more potent and easier to obtain than prescription opioids. In that setting, reducing prescription exposure is a prevention measure, but it is not by itself a sufficient explanation for mortality trends; substitution toward illicit drugs can alter risk in complex ways.\n\nHHS’s announcement attributes the progress to policies across administrations, including prescribing changes, fentanyl enforcement and treatment programs, and highlights the 2025 SUPPORT Act reauthorization and a 2026 federal recovery initiative. The analyses document trends but do not isolate the effect of any one law or administration. They rely on population-adjusted IQVIA pharmacy data and identify limitations in channel coverage and treatment definitions. The authors emphasize that prescription counts alone can miss dosage and patient changes, while legal authority for treatment does not guarantee practical access to diagnosis, medication, follow-up and support. The results support cautious monitoring across multiple measures; they do not show that all opioid-related deaths have reached a decade low or that the same trend holds for every community.","title":"Prescription opioid exposure falls as treatment medication reach expands","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026"},{"api_url":"https://newsverum.com/api/v1/articles/opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026"}],"url":"https://newsverum.com/en/news/opioid-prescription-exposure-falls-as-medication-treatment-reach-expands-us-2026"},"version":"1"}
